REFRACTORY NEUROBLASTOMA

This study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. Participants have advanced solid tumors, lymphomas, o…

This early-stage trial tests a combination of lenalidomide (a chemotherapy drug) and dinutuximab (an antibody therapy), with or without isotretinoin, in children and young adults with neuroblastoma that has not responded to treatment or has returned. The main goal is to find the …

This study tests a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have either returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors. Only 3 participants were enrolled,…

This study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or recurrent solid tumors, lymphoma, or histiocytic disorders have a specific genetic change called an NTRK fusion. The drug works by blocking enzymes that help cancer cells gr…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancer has returned or spread and has a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 5 participants received the drug…

This study tested the drug ensartinib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers had come back or stopped responding to treatment and had specific gene changes (ALK or ROS1). The goal was to see if the drug could shrink o…

This study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had spread, returned, or stopped responding to treatment. The drug targets tumors with specific changes in FGFR genes. The main goal was to see if the drug could shrink or stop t…

This study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and have many genetic mutations. The goal was to see if the combination could shrink tumors or help patients l…

This study tests whether adding eflornithine (DFMO) to a standard chemo-immunotherapy regimen (irinotecan, temozolomide, and dinutuximab) helps children whose neuroblastoma has returned or stopped responding to treatment. About 94 children will be randomly assigned to receive the…

This study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …

This early-stage trial tests a personalized cell therapy called GD2CART for children and young adults with osteosarcoma or neuroblastoma that has returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack ca…

This study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…